Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma

Cereblon (CRBN) is essential for the anti-myeloma (MM) activity of immunomodulatory drugs (IMiDs), such as thalidomide and lenalidomide. However, the clinical implications of CRBN in MM patients are unclear. Using immunohistochemical (IHC) staining on paraffin-embedded bone marrow sections, the expr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Huang, Shang-Yi, Lin, Chung-Wu, Lin, Hsiu-Hsia, Yao, Ming, Tang, Jih-Luh, Wu, Shang-Ju, Chen, Yao-Chang, Lu, Hsiao-Yun, Hou, Hsin-An, Chen, Chien-Yuan, Chou, Wen-Chien, Tsay, Woei, Chou, Sheng-Je, Tien, Hwei-Fang
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2014
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4082140/
https://ncbi.nlm.nih.gov/pubmed/24687382
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-014-2063-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados